A synthetic estrogen that has been used as a hormonal antineoplastic agent.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Hexestrol. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Hexestrol. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hexestrol. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Hexestrol. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hexestrol. |
| Lenalidomide | Hexestrol may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Hexestrol is combined with Ospemifene. |
| Ropinirole | Hexestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Hexestrol may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Hexestrol may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Hexestrol may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Hexestrol may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Hexestrol may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Hexestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Hexestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Hexestrol may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Hexestrol may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Hexestrol may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Hexestrol may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Hexestrol may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Hexestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Hexestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Hexestrol may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Hexestrol may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Hexestrol may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Hexestrol may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Hexestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Hexestrol may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Hexestrol may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Hexestrol may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Hexestrol may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Hexestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Hexestrol may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Hexestrol may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Hexestrol may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Hexestrol may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Hexestrol may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Hexestrol may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Hexestrol may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Hexestrol may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Hexestrol may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Hexestrol may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Hexestrol may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Hexestrol may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Hexestrol may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Hexestrol may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Hexestrol may increase the thrombogenic activities of Bavituximab. |
| CR002 | Hexestrol may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Hexestrol may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Hexestrol may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Hexestrol may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Hexestrol may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Hexestrol may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Hexestrol may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Hexestrol may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Hexestrol may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Hexestrol may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Hexestrol may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Hexestrol may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Hexestrol may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Hexestrol may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Hexestrol may increase the thrombogenic activities of Ustekinumab. |
| Trastuzumab emtansine | Hexestrol may increase the thrombogenic activities of Trastuzumab emtansine. |
| PRO-542 | Hexestrol may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Hexestrol may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Hexestrol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Hexestrol may increase the thrombogenic activities of RI 624. |
| Stamulumab | Hexestrol may increase the thrombogenic activities of MYO-029. |
| CT-011 | Hexestrol may increase the thrombogenic activities of CT-011. |
| Leronlimab | Hexestrol may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Hexestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Hexestrol may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Hexestrol may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Hexestrol may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Hexestrol may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Hexestrol may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Hexestrol may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Hexestrol may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Hexestrol may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Hexestrol may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Hexestrol may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Hexestrol may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Hexestrol may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Hexestrol may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Hexestrol may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Hexestrol may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Hexestrol may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Hexestrol may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Hexestrol may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Hexestrol may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Hexestrol may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Hexestrol may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Hexestrol may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Hexestrol may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Hexestrol may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Hexestrol may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Hexestrol may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Hexestrol may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Hexestrol may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Hexestrol may increase the thrombogenic activities of Reslizumab. |